Marksans Pharma Limited has informed the Exchange regarding Board meeting held on August 12, 2025.
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma's board approved its Q1 FY26 unaudited financial results (both standalone and consolidated), reviewed by statutory auditor MSKA & Associates with an unmodified (clean) opinion. On a standalone basis, revenue from operations rose about 25.6% year-on-year to Rs 3,197.34 million (vs Rs 2,545.27 million in Q1 FY25), while profit after tax jumped roughly 50% to Rs 480.56 million (vs Rs 320.15 million), pushing EPS to Rs 1.06 from Rs 0.71. On a consolidated basis, revenue grew a modest 5% to Rs 6,199.89 million, but profit after tax actually fell about 35% to Rs 582.02 million (vs Rs 890.67 million) and EPS dropped to Rs 1.29 from Rs 1.96, hurt by higher costs and a Rs 37.73 million net FX loss in other income (vs a Rs 26.11 million gain a year ago).
Positive read-through at the standalone level on strong revenue and profit growth, but the sharp drop in consolidated profit despite steady revenue growth is a red flag — investors should watch for sustained margin pressure and FX volatility. Expect a mixed market reaction; the stock may see limited upside until consolidated profitability stabilises.